Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer
Status:
Not yet recruiting
Trial end date:
2026-09-15
Target enrollment:
Participant gender:
Summary
This trial is a single arm open-label, phase II aiming to assess the clinical activity of
niraparib in chemotherapy-naïve biomarker-selected pancreatic cancer patients.